CODX (Co-Diagnostics) Additional Paid-In Capital : $103.70 Mil(As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Co-Diagnostics Additional Paid-In Capital?

Co-Diagnostics's quarterly additional paid-in capital increased from Sep. 2024 ($100.92 Mil) to Dec. 2024 ($102.47 Mil) and increased from Dec. 2024 ($102.47 Mil) to Mar. 2025 ($103.70 Mil).

Co-Diagnostics's annual additional paid-in capital increased from Dec. 2022 ($88.47 Mil) to Dec. 2023 ($96.81 Mil) and increased from Dec. 2023 ($96.81 Mil) to Dec. 2024 ($102.47 Mil).

Co-Diagnostics Additional Paid-In Capital Historical Data

The historical data trend for Co-Diagnostics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Additional Paid-In Capital Chart

Co-Diagnostics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

49.16

80.27

88.47

96.81

102.47

Co-Diagnostics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															98.38	99.88	100.92	102.47	103.70

Co-Diagnostics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Co-Diagnostics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Co-Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (NAS:CODX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

0A50:UK C97:Germany

Address

2401 South Foothill Drive, Salt Lake City, UT, USA, 84109

Website

https://www.codiagnostics.com

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Executives

Brian Lee Brown	officer: Chief Financial Officer	5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096
Ted Murphy	director	64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1
Eugene Durenard	director	2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Dwight H Egan	director, officer: CEO and President	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Richard S Serbin	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
James B Nelson	director	26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010
Reed L Benson	officer: CFO and Secretary	7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047
Edward L. Murphy	director	2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Brent Satterfield	director, officer: Chief Science Officer	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
America 2030 Capital, Llc	10 percent owner	1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144
Edward Borkowski	director	1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Frank J Kiesner	director	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Reagents, Llc	10 percent owner	8160 S. HIGHLAND DR, SANDY UT 84093
Legends Capital Group, Llc	10 percent owner	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124